05:14 PM EDT, 04/01/2024 (MT Newswires) -- SIGA Technologies ( SIGA ) said late Monday it will drive international promotion of oral TPOXX under an amended deal with Meridian Medical Technologies, effective June 1.

The amendment extends the deal's term by two years with respect to specific territories, including the EU, and gives SIGA ( SIGA ) primary responsibility for promoting oral TPOXX while maintaining the contractual relationship with Meridian for continuity for key customer relationships.

SIGA ( SIGA ) said the US Food and Drug Administration approved the oral formulation of TPOXX to treat smallpox in 2018, while the IV formulation was approved for the same indication in 2022.

Price: 8.85, Change: +0.06, Percent Change: +0.68